Breaking News, Financial News

Financial Report: BMS

Eliquis and AZ diabetes deal drive earnings in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BMS   1Q Revenues: $3.8 billion (-1%) 1Q Earnings: $936 million (+54%) Comments: The company completed the sale of its diabetes business to AstraZeneca, receiving $3.3 billion in closing and milestone payments during the quarter. Sprycel sales were up 19% to $342 million. Yervoy sales grew 18% to $271 million. Orencia sales were up 13% to $363  million, and Baraclude sales grew 11% to 406 million. Sustiva franchise sales were down 18% to $319 million due to generic competition. Global revenues...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters